We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > zalifrelimab

News List

Agenus Enters into Clinical Collaboration with Nelum for Zalifrelimab Combination americanpharmaceuticalreview
February 03, 2021
Agenus has entered into a clinical collaboration with Nelum to evaluate the safety and efficacy of zalifrelimab, Agenus’ anti-CTLA-4 antibody, in combination with NLM-001, Nelum’s small molecule hedgehog inhibitor, and chemotherapy for first-line ...
Immunotherapies to treat cervical cancer show promise in Phase II trials europeanpharmaceuticalreview
October 16, 2020
Novel programmed cell death protein 1 immunotherapies for cervical cancer have demonstrated success in two Phase II clinical trials in the US.
Agenus Receives Fast Track Designation for Cervical Cancer Treatment americanpharmaceuticalreview
March 17, 2020
Agenus announced the U.S. Food and Drug Administration (FDA) has granted Agenus Fast Track designation for investigation of balstilimab [PD-1] in combination ...